Q/C Technologies, Inc. (QCLS)
| Market Cap | 31.88M +1,330.3% |
| Revenue (ttm) | n/a |
| Net Income | -14.98M |
| EPS | -8.66 |
| Shares Out | 7.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 791,152 |
| Open | 3.760 |
| Previous Close | 3.770 |
| Day's Range | 3.760 - 4.150 |
| 52-Week Range | 2.500 - 33.560 |
| Beta | 2.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About QCLS
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various... [Read more]
Financial Performance
Financial StatementsNews
Q/C Technologies launches optical processing unit initiative
Q/C Technologies (QCLS) announced the launch of a new initiative to design and prototype a proprietary optical processing unit aimed at tackling the growing performance and energy constraints in artif...
Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference
New initiative aimed at developing optical computing technologies to overcome the performance and energy limitations of traditional electronic architectures
Q/C Technologies files $100M mixed securities shelf
17:18 EST Q/C Technologies (QCLS) files $100M mixed securities shelf
Q/C Technologies appoints Voss to Board of Directors
Q/C Technologies (QCLS) announced the appointment of Chelsea Voss to its Board of Directors.
Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors
New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C Technologies” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced...
Q/C Technologies Inc trading resumes
09:37 EST Q/C Technologies (QCLS) Inc trading resumes
Q/C Technologies Inc trading halted, volatility trading pause
09:32 EST Q/C Technologies (QCLS) Inc trading halted, volatility trading pause
Q/C Technologies appoints Martin Shkreli as senior advisor
Q/C Technologies (QCLS) announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage grow...
Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli
New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (“Q/C” or “the Company”), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkr...
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR
Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”. According to him, the photonic compu...
Q/C Technologies enters collaboration with LightSolver
Q/C Technologies (QCLS) announced its collaboration with LightSolver, the inventor and owner of the quantum-class laser processing unit technology. Through this collaboration, Q/C becomes the first cl...
Q/C Technologies Introduces Proprietary qc-LPU100™ Brand of Quantum-Class Laser Processing Units
Breakthrough LPUs designed to compute at quantum-class speed using natural light instead of electrical signals to achieve quantum computer speeds
Q/C Technologies appoints Steven Frankel as senior quantum advisor
Q/C Technologies (QCLS) announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor. Dr. Frankel will help guide the Company’s ongoing efforts in quantum-class photonic computing to a...
Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives
Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (Nasdaq: QCLS) (...
Q/C Technologies files to sell 6.51M shares of common stock for holders
17:31 EDT Q/C Technologies (QCLS) files to sell 6.51M shares of common stock for holders
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
NEW YORK--(BUSINESS WIRE)---- $QCLS--Q/C Technologies, Inc. (Nasdaq: QCLS), formerly TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), (“Q/C” or “the Company”), today announced that its common stock will begi...
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company”) today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin t...
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals Inc. (Nasdaq: TNFA), (“TNF” or the “Company”) today announced that it received written notice from the Nasdaq Stock Market on September 16, 202...
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced its participation in the H.C. Wainwright & Co. 27th Annual Global Investment Conf...
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced the closing of a $7.0 million private placement financing of convertible preferre...
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNFA, “TNF”) by an a...
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced that it has entered into a licensing agreement for an innovative processing accel...
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmun...
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmun...
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmun...